If you have been reading about Epitalon and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-14. Numbers and descriptions here follow the published literature rather than marketing material.
The compound is generally described as a synthetic analogue of a fragment isolated from a pineal gland extract. Researchers associated with the Saint Petersburg Institute of Bioregulation and Gerontology introduced it during the 1980s and 1990s while studying short peptides from animal tissue. The original extract, called epithalamin, is a heterogeneous mixture, whereas epitalon is a single defined sequence. That distinction matters because findings reported for the extract are not automatically findings about the pure tetrapeptide, and claims about broader biological effects remain a separate question from the chemical identity described here.
Residue composition is the property that most cleanly separates verified material from mislabelled samples. Alanine, glutamate, aspartate and glycine appear in that order from the N-terminus, and the two acidic residues sit in the middle of the chain. Because the peptide is short, it can be produced by solid-phase synthesis and characterised by mass spectrometry without ambiguity. Any reported sample whose measured mass departs substantially from 390 daltons is a different compound or a degraded mixture rather than epitalon.
Epitalon is a synthetic tetrapeptide whose four residues are alanine, glutamate, aspartate and glycine, commonly abbreviated AEDG. Its molecular formula is C14H22N4O9 and its monoisotopic mass is near 390.35 daltons. The peptide carries two acidic side chains, so it is neutral to negatively charged in most aqueous buffers. Published reference summaries usually list it under both spellings, epitalon and epithalon, and treat the two names as the same material.
Most experimental work has been carried out in cell culture and animal models. Several reports describe changes in telomerase activity and proliferation in cultured cells, while rodent studies have examined lifespan, melatonin rhythm and reproductive endpoints. Human data remain limited, and much of the published clinical material consists of small trials with incomplete reporting of methods and controls. Whether the cell and animal findings translate into measurable effects in people is an open question, and the mechanistic basis of the reported telomerase changes is not fully established.
Discussions in the literature often conflate three distinct entities: the pineal extract epithalamin, the isolated tetrapeptide AEDG, and commercial preparations sold under similar names. Reviews citing older Russian-language studies sometimes omit detail on purity, route of administration and control groups, which makes cross-study comparison difficult. Researchers working with the compound generally note the need for independent replication, standardized enzyme assays, and clearer reporting of peptide identity. These caveats are relevant when weighing claims that appear in secondary sources rather than in primary reports.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C14H22N4O9 | Derived from the four constituent residues |
| Molecular mass | About 390.35 Da | Monoisotopic value, confirmed by mass spectrometry |
| Residue sequence | Ala-Glu-Asp-Gly | Read from the N-terminus to the C-terminus |
| Common synonyms | Epithalon; AEDG | Both forms appear in reference catalogues |
| Net charge near neutral pH | Negative | Two acidic side chains give a low isoelectric point |
Literature searches for this compound must account for several spelling variants. Indexing databases contain epitalon, epithalon, epithalone, and AEDG, and relevant records are scattered across Russian-language and English-language journals that do not consistently cross-cite. Early publications describe the parent extract as a mixture of many peptides, whereas later work addresses the single synthetic tetrapeptide. That shift in nomenclature complicates comparison between studies, because extract data and tetrapeptide data are sometimes cited interchangeably. A search strategy omitting the alternate spellings will return an incomplete set of references.
Reported biological findings come mainly from cell culture and rodent experiments. Those studies describe changes in telomerase catalytic subunit expression, melatonin rhythm amplitude, and antioxidant enzyme activity after peptide exposure. Human data are sparse and consist of small trials with limited blinding and inconsistent endpoints. The proposed mechanisms remain hypotheses rather than established facts, and there is no consensus on whether effects observed in animals carry over to people. Independent replication outside the original research groups is limited, which is a recognised gap in the published literature.
Epitalon is a synthetic tetrapeptide whose sequence is alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. It was developed in Russia during the 1980s and 1990s by investigators associated with the St. Petersburg Institute of Bioregulation and Gerontology, who studied short peptides as regulators of gene expression and tissue function. The alternative spelling epithalon appears interchangeably in the literature, and the two names refer to the same molecule. Outside Russia it is encountered chiefly as a research chemical rather than a licensed medicine, and it holds no approval from the United States Food and Drug Administration or the European Medicines Agency.
The peptide is a synthetic analogue of epithalamin, a preparation extracted from bovine pineal glands. Investigators sought a short, chemically defined molecule that would reproduce some of the endocrine and gerontological observations attributed to the glandular extract. Proposed mechanisms centre on induction of telomerase activity, an effect reported in cultured human somatic cells in the early 2000s, together with influences on melatonin secretion and neuroendocrine regulation. Those mechanisms remain incompletely characterised, and the reported telomerase response has not been consistently reproduced by independent groups working in comparable systems.
Epitalon is a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, abbreviated AEDG. Its molecular formula is C14H22N4O9 and its calculated monoisotopic mass is approximately 390.35 daltons. The compound does not occur naturally as a free peptide; it is produced by solid-phase peptide synthesis. Because it contains two acidic residues and no basic residues, the neutral form carries a net negative charge at physiological pH. This charge profile influences how the peptide behaves in solution and during chromatographic analysis.
Laboratory-grade epitalon is typically supplied as a lyophilized powder. Purity is commonly assessed with reverse-phase high-performance liquid chromatography, often paired with mass spectrometry to confirm molecular identity. Amino acid analysis and peptide mapping can provide additional confirmation of sequence. Certificates of analysis for research materials frequently report purity above 95 percent, although the methods behind such figures vary between suppliers. The absence of a pharmacopeial monograph means that no single standardized assay defines the compound, so reported results depend on the analytical protocol chosen.
Storage recommendations center on limiting moisture, heat, and light. The dry powder is generally kept at minus 20 degrees Celsius, and some suppliers recommend minus 80 degrees for long-term archival. Once dissolved, solutions are usually aliquoted and frozen to avoid repeated freeze-thaw cycles, which can promote aggregation or degradation. Aqueous stability depends on pH and concentration, and buffered saline is often preferred over plain water for biological work. Stability data specific to epitalon remain limited, so general peptide-handling practices are applied by analogy rather than from product-specific validation.
Epitalon is a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. It was designed at the St. Petersburg Institute of Bioregulation and Gerontology as a short, chemically defined analogue of epithalamin, a fraction obtained from bovine pineal tissue. Small peptide bioregulators of this type formed a long-running line of work there from the 1980s onward. Because the molecule is produced by solid-phase synthesis rather than extraction, its composition is exact and its purity can be measured directly.
The most frequently cited proposed action is induction of telomerase, the enzyme that adds repeat sequences to chromosome ends. Cell-culture work from the originating group reported higher telomerase reverse transcriptase expression and measurable telomere elongation in human somatic cells after exposure. How a four-residue peptide would reach nuclear gene regulation is not established, and no cell-surface receptor or uptake route has been identified. Additional reports describe changes in melatonin secretion, antioxidant enzyme activity and lipid peroxidation in aged animals, but these findings remain mechanistically unconnected to the telomerase observation.
The chemistry of plutonium was found to resemble uranium after a few months of initial study. Early research was continued at the secret Metallurgical Laboratory of the University of Chicago. On August 20, 1942, a trace quantity of this element was isolated and measured for the first time. About 50 micrograms of plutonium-239 combined with uranium and fission products was produced and only about 1 microgram was isolated. This procedure enabled chemists to determine the new element's atomic weight. On December 2, 1942, on a racket court under the west grandstand at the University of Chicago's Stagg Field, researchers headed by Enrico Fermi achieved the first self-sustaining chain reaction in a graphite and uranium pile known as CP-1. Using theoretical information garnered from the operation of CP-1, DuPont constructed an air-cooled experimental production reactor, known as X-10, and a pilot chemical separation facility at Oak Ridge. The separation facility, using methods developed by Glenn T. Seaborg and a team of researchers at the Met Lab, removed plutonium from uranium irradiated in the X-10 reactor. Information from CP-1 was also useful to Met Lab scientists designing the water-cooled plutonium production reactors for Hanford. Construction at the site began in mid-1943. In November 1943 some plutonium trifluoride was reduced to create the first sample of plutonium metal: a few micrograms of metallic beads. Enough plutonium was produced to make it the first synthetically made element to be visible with the unaided eye.
==== Limitation on overall itemized deductions ==== Itemized deductions are reduced by 2/37 of the lesser of the amount of the itemized tax deductions or the taxable income that is within the 37%-rate marginal tax bracket. As an exception, the qualified business income deduction under 26 U.S.C. § 199A is not subject to the limitation.
In the late 17th century, the Shroud was placed in the chapel designed for that purpose by architect Guarino Guarini and attached to both the cathedral and the Royal Palace of Turin. It remained there until 1993, when it was moved into the cathedral. Repairs were made to the Shroud in 1694 by Sebastian Valfrè, improving upon the earlier patching by the Poor Clares. Further repairs were made in 1868 by Princess Maria Clotilde of Savoy. The Shroud was first photographed in 1898, during a public exhibition. The Shroud remained the property of the House of Savoy until 1983, when it was bequeathed to the Holy See according to the terms of the will of the former king Umberto II of Italy. A fire, possibly caused by arson, threatened the Shroud on 11 April 1997. In 2002 the Holy See had the Shroud restored. The cloth backing and thirty patches were removed, making it possible to photograph and scan the reverse side of the cloth, which had been hidden from view. A faint part-image of the body was found on the back of the Shroud in 2004. The Shroud was placed back on public display (the 18th time in its history) in Turin from 10 April to 23 May 2010; and according to Church officials, more than 2 million visitors came to see it. On Holy Saturday (30 March) 2013, images of the Shroud were streamed on various websites as well as on television for the first time in 40 years.
== History == This condition was first described in 1954 by Janeway, who reported five cases of the disease in children. In 1957 it was further characterized as "a fatal granulomatosus of childhood". The underlying cellular mechanism that causes chronic granulomatous disease was discovered in 1967, and research since that time has further elucidated the molecular mechanisms underlying the disease. Use of antibiotic prophylaxis, surgical abscess drainage, and vaccination led to the term "fatal" being dropped from the name of the disease as children survived into adulthood.
=== Public engagement === While all fadas form relationships between financially insecure youths, their particular goals differ. Some simply focus on conversation, with no particular agendas, while others function like NGOs. In contrast to fadas with civic missions, some function as criminal gangs, engaging in petty theft and dealing drugs such as amphetamines, and some add the opioid tramadol to their tea. Other fadas focus on art and music. Many fadas play a role in security, being active at night when they can keep watch for criminals and track people entering the neighborhood. In the absence of official security forces, fadas gain support from neighbors, and shopkeepers sometimes reward them with tea, sugar, and beans. Fadas describe themselves as "making the neighborhood safe"; they boast about capturing thieves without inflicting violence. Many neighbors affirm that the presence of fadas decreases crime, though some worry about fadas getting into fights. As fadantchés contribute to security by sitting outside, they display a positive aspect to the idleness caused by their unemployment. Some fadantchés become involved in violent vigilantism. In Zinder, such groups are known as palais, distinguished from fadas as they more closely resemble gangs. They are influenced by the masculine ideals of gangs in the United States, with activities focused on sex, drugs, and violence. Palais have hierarchical structures with an individual leader. They are particularly common in impoverished neighborhoods. People in Zinder often blame crimes on palais members.
Sources: en.wikipedia.org
Other 1,2- and 1,3-dithiols give related 1,3-dithiolanes (five-membered) and 1,3-dithianes (six-membered rings). Diols such as ethylene glycol undergo analogous reactions to give 1,3-dioxolanes. One distinguishing feature of the dithiolanes and dithianes derived from aldehydes is that the methyne group can be deprotonated and the resulting carbanion alkylated. 1,2-Ethanedithiol has been used as a scavenger in peptide cleavage synthesis. Like 1,3-propanedithiol, 1,2-ethanedithiol readily forms metal thiolate complexes. Illustrative is the synthesis of the derivative diiron ethanedithiolate hexacarbonyl upon reaction with triiron dodecacarbonyl: Fe3(CO)12 + C2H4(SH)2 → Fe2(S2C2H4)(CO)6 + H2 + Fe(CO)5 + CO Ethane-1,1-dithiol
Human chorionic gonadotropin (hCG) is a hormone for the maternal recognition of pregnancy produced by trophoblast cells that are surrounding a growing embryo (syncytiotrophoblast initially), which eventually forms the placenta after implantation. The presence of hCG is detected in some pregnancy tests (HCG pregnancy strip tests). Some cancerous tumors produce this hormone; therefore, elevated levels measured when the patient is not pregnant may lead to a diagnosis of cancer and, if high enough, of paraneoplastic syndromes. It is unknown however whether this production is a contributing cause or an effect of carcinogenesis. The pituitary analogue of hCG, luteinizing hormone (LH), is produced in the pituitary gland of males and females of all ages. Beta-hCG is initially secreted by the syncytiotrophoblast.
Control patterns describe how a perturbation to a given parameter affects the steady-state level of a given variable. For example, a concentration control coefficient can describe how the overexpression of a specific enzyme can influence steady-state metabolite concentrations. Flux control coefficients are similar in that they describe how a perturbation in a given enzyme affects steady-state flux through a pathway. Such coefficients can be written in terms of elasticity coefficients. Elasticity coefficients are local properties that describe how a single reaction is influenced by changes in the substrates and products that might influence the rate. For example, given a reaction such as: S ⟶ v P {\displaystyle S{\stackrel {v}{\longrightarrow }}P} we will assume it has a rate of reaction of v {\displaystyle v} . This reaction rate can be influenced by changes in the concentrations of substrate S {\displaystyle S} or product P {\displaystyle P} . This influence is measured by an elasticity which is defined as: ε s v = ∂ v ∂ s s v
== Medical uses == Venlafaxine is used primarily for the treatment of depression, general anxiety disorder, social phobia, panic disorder, and vasomotor symptoms. Concerns that noradrenergic reuptake might precipitate anxiety have not been borne out in randomized trials: a 2016 systematic review of 52 double-blind, placebo-controlled studies (mostly with venlafaxine or duloxetine) found clinically significant improvements in anxiety symptoms and no signal for treatment-emergent anxiety attributable to SNRIs. Venlafaxine has been used off label for the treatment of diabetic neuropathy and migraine prevention. It may work on pain via effects on the opioid receptor. It has also been found to reduce the severity of 'hot flashes' in menopausal women and men on hormonal therapy for the treatment of prostate cancer. Due to its action on both the serotonergic and adrenergic systems, venlafaxine is also used as a treatment to reduce episodes of cataplexy, a form of muscle weakness, in patients with the sleep disorder narcolepsy. Some open-label and three double-blind studies have suggested the efficacy of venlafaxine in the treatment of attention deficit-hyperactivity disorder (ADHD). Clinical trials have found possible efficacy in those with post-traumatic stress disorder (PTSD). Case reports, open trials and blinded comparisons with established medications have suggested the efficacy of venlafaxine in the treatment of obsessive–compulsive disorder.
Sources: en.wikipedia.org
The DSM-5 characterizes diagnosis under several categories—mild, moderate, severe, and extreme—each determined by the number of binges the patient exhibits per week. Mild: 1–3 episodes per week, Moderate: 4–7 episodes per week, Severe: 8–13 episodes per week, Extreme: 14 or more episodes per week Further, the remission states are classified under the following. Partial Remission: Following a previous diagnosis, the average frequency of binge eating episodes decreases to less than one episode per week for a sustained period. Full Remission: Following a previous diagnosis, none of the criteria have been met for a sustained period.
=== Tobacco settlement === In 1988, Louisiana was one of 46 states to enter into a settlement with tobacco companies over smoking-related illnesses whereby each state could choose between annual payments or a smaller lump sum. Louisiana took the annual payments. As treasurer, Kennedy structured a deal to auction off part of the annual payments in exchange for a lump sum to hedge against the possibility that the tobacco companies could go bankrupt. At the time, Kennedy said, "If your rich uncle died and left you $4.4 billion, all of it in Philip Morris stock, what would you do? I would diversify." The proceeds from that sale were invested in trust funds earmarked for education, health care, and TOPS—a higher-education scholarship program. Kennedy opposed future sales of the debt. He argued that his early sale was only a hedge against a potential bankruptcy of the tobacco companies and should not be used as a short term fund to address immediate spending. In 2007, the Louisiana State Bond Commission voted to sell more of the settlement and Kennedy was the lone opposition vote. In 2015, Governor Jindal announced a plan to sell the remainder of the tobacco settlement in one lump sum of $751 million to help him address budget shortfalls rather than accepting the remaining $1.2 billion in annual payments. Kennedy opposed the plan, saying that taking the lump sum would be a "bonehead move" that the legislature would not support and adding: "I’ve talked to a number of legislators.
== Dextran prodrug == Dextran prodrugs are chemically linked drug-polymer complexes in which enzymatic processes and hydrolysis in vivo cause the drug to become pharmacologically active. Therapeutic agents can be linked to dextran via an ester bond which can be hydrolyzed slowly by esterases to produce sustained, stable drug release. Drug-dextran complexes can also be formed by chemical linkage through an amide bond, which is hydrolyzed by amidase. Prodrugs coupled by amide bonds provide much slower drug release than by ester bonds. Succinic acid and glutaric acid carboxyl groups, amino acids, pH and reductivity sensitive disulfide bonds, and click chemistry are also methods of coupling drugs to dextran.
Sources: en.wikipedia.org
It is a four-amino-acid peptide built from alanine, glutamate, aspartate and glycine in that order. Its formula is C14H22N4O9, and it is made by chemical synthesis rather than extracted from tissue. The synthetic peptide is a single defined molecule, unlike the pineal extracts it is often compared with.
No. The two spellings refer to the same tetrapeptide, and the difference reflects transliteration from Russian. Laboratories and catalogues use both forms interchangeably. The material is also indexed as AEDG, taken from the one-letter codes of its residues.
Epithalamin is a mixed preparation derived from animal pineal tissue and contains many peptides. Epitalon is one synthetic sequence chosen for study from that broader mixture. Statements about one do not transfer directly to the other.
It is a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, often abbreviated AEDG. The molecule is linear and contains no modified residues, so it is fully described by its sequence.